Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (70.56%), COSCO Shipping Energy (69.91%), and GCL-Poly Energy (69.65%) [1][2] - Xiaomi Group-W, Meituan-W, and Pop Mart have seen the largest increases in holding amounts over the last five trading days, with increases of +1.967 billion, +1.692 billion, and +1.514 billion respectively [1][2] - The companies with the largest decreases in holding amounts over the same period include Innovent Biologics (-2.053 billion), SMIC (-1.978 billion), and Alibaba-W (-1.651 billion) [1][2] Hong Kong Stock Connect Latest Holding Ratios - China Telecom (00728): 9.793 billion shares, 70.56% holding ratio [1] - COSCO Shipping Energy (01138): 906 million shares, 69.91% holding ratio [1] - GCL-Poly Energy (01330): 282 million shares, 69.65% holding ratio [1] - China Shenhua (01088): 2.284 billion shares, 67.62% holding ratio [1] - Kaisa Group (01108): 168 million shares, 67.37% holding ratio [1] Recent Increases in Holdings (Last 5 Trading Days) - Xiaomi Group-W (01810): +1.967 billion, +42.788 million shares [1] - Meituan-W (03690): +1.692 billion, +17.904 million shares [1] - Pop Mart (09992): +1.514 billion, +5.498 million shares [1] - China Mobile (00941): +1.438 billion, +16.863 million shares [1] - Huahong Semiconductor (01347): +1.434 billion, +18.918 million shares [1] Recent Decreases in Holdings (Last 5 Trading Days) - Innovent Biologics (01801): -2.053 billion, -23.641 million shares [2] - SMIC (00981): -1.978 billion, -28.625 million shares [2] - Alibaba-W (09988): -1.651 billion, -10.691 million shares [2] - Tencent Holdings (00700): -1.475 billion, -2.426 million shares [2] - Yingfu Fund (02800): -1.259 billion, -48.701 million shares [2]

Key Points - The top three stocks with net inflows from southbound funds on October 15 are Ying'en Bio-B (09606) with 882 million, Alibaba-W (09988) with 831 million, and China Merchants Bank (03968) with 683 million [1][2] - The top three stocks with net outflows are the Tracker Fund of Hong Kong (02800) with -8.571 billion, Hang Seng China Enterprises (02828) with -3.336 billion, and SMIC (00981) with -660 million [1][2] - In terms of net inflow ratios, Uni-President China (00220), GX Hangseng Technology (02837), and Anjoy Foods (02648) lead with 64.68%, 64.41%, and 59.18% respectively [1][2] - The stocks with the highest net outflow ratios are China International Marine Containers (02039) at -56.29%, Fudan Zhangjiang (01349) at -56.18%, and Weishi Jiajie (00856) at -44.42% [1][2] Net Inflow Rankings - The top ten stocks by net inflow include Ying'en Bio-B (09606) with 882 million, Alibaba-W (09988) with 831 million, and China Merchants Bank (03968) with 683 million [2] - Other notable stocks in the top ten include Kuaishou-W (01024) with 497 million and Huahong Semiconductor (01347) with 433 million [2] Net Outflow Rankings - The top three stocks by net outflow are the Tracker Fund of Hong Kong (02800) with -8.571 billion, Hang Seng China Enterprises (02828) with -3.336 billion, and SMIC (00981) with -660 million [2] - Additional stocks with significant outflows include Southern Hangseng Technology (03033) with -653 million and Laopu Gold (06181) with -502 million [2] Net Inflow Ratio Rankings - The highest net inflow ratios are seen in Uni-President China (00220) at 64.68%, GX Hangseng Technology (02837) at 64.41%, and Anjoy Foods (02648) at 59.18% [2][3] - Other companies with notable inflow ratios include Jianfa International Group (01908) at 48.81% and China Gas (00384) at 44.55% [3] Net Outflow Ratio Rankings - The stocks with the highest net outflow ratios include China International Marine Containers (02039) at -56.29%, Fudan Zhangjiang (01349) at -56.18%, and Weishi Jiajie (00856) at -44.42% [3] - Other companies with significant outflow ratios include Jinyu Group (02009) at -43.17% and Weilu Group (01196) at -41.11% [3]

Core Viewpoint - The company, Ying'en Biotechnology-B, announced plans to issue ordinary shares for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, subject to market conditions and necessary approvals [1] Group 1 - The board of directors has resolved to issue shares that will be traded in RMB [1] - The issuance is contingent upon further approval from the board, shareholder meeting, and regulatory authorities [1]

Core Viewpoint - The company, Ying'en Biotechnology (09606.HK), announced its decision to propose the issuance of RMB shares and listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, contingent upon market conditions and necessary approvals [1] Group 1 - The board of directors has made a resolution regarding the issuance of shares [1] - The listing is subject to further approval from the board, shareholders, and regulatory authorities [1]

Core Viewpoint - The company, InnoCare Pharma-B (09606.HK), announced plans to issue ordinary shares to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with trading in Renminbi [1] Group 1 - The issuance of shares is subject to market conditions, further approval from the board, shareholder approval at the company's general meeting, and necessary regulatory approvals [1]

Core Viewpoint - The company, Ying'en Biotechnology-B (09606), plans to issue ordinary shares to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with trading in Renminbi [1] Group 1 - The board of directors has resolved to propose the issuance of Renminbi shares, subject to market conditions, further board approval, shareholder approval at the general meeting, and necessary regulatory approvals [1] - As of the date of the announcement, there are no other plans regarding the proposed issuance of Renminbi shares, nor has the board made any applications to relevant regulatory bodies [1]

映恩生物-B(09606)公布，于2025年10月17日，公司董事会决议公司拟发行将于上海证券交易所科创板 上市并以人民币买卖的普通股。建议发行人民币股份取决于及受限于(其中包括)市场状况、董事会的进 一步批准、股东于公司股东大会上的批准及必要监管机构的批准。 于本公告日期，除建议发行人民币股份的初步建议及本公告另行披露的资料外，董事会并无有关建议发 行人民币股份的任何其他计划，亦无就建议发行人民币股份向相关监管机构作出任何申请。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 股東及有意投資者務請注意，董事會批准的建議發行人民幣股份的初步建議可能 會有所變動。建議發行人民幣股份的任何具體計劃（倘由本公司作出）以及建議發 行人民幣股份的預期時間將受限於（其中包括）董事會進一步批准及股東於本公司 股東大會上的批准以及必要的監管批准。因此，建議發行人民幣股份可能會或可 能不會進行。本公司股東及有意投資者務請注意，概不保證建議發行人民幣股份 將會付諸實行或於何時實行，因此，於買賣本公司股份時務請審慎行事。 Duality Biotherapeutics, Inc. 映恩生物 （根據開曼群島法律註冊成立的有限公司） （股份代號：9606） 內幕消息 建議發行人民幣股份及 於上海證券交易所科創板上市 本公告乃由映恩生物（「本公司」）根據香港聯合交易所有限公司證券上市規則（「上 市規則」）第13.09 (2)條及證券及期貨條例（香港法例第571章）第XIVA部項下之內 幕消息條文（定義見上市規 ...

Core Insights - The biotechnology sector in the Hong Kong stock market has shown strong performance, with several stocks experiencing significant gains today, particularly药捷安康-B which surged over 30% [1] Stock Performance Summary - 药捷安康-B: Increased by 31.25%, latest price at 218.000, total market value of 86.524 billion, year-to-date increase of 1557.79% [2] - 康宁杰瑞制药-B: Increased by 7.15%, latest price at 14.680, total market value of 14.245 billion, year-to-date increase of 319.43% [2] - 帝王国际投资: Increased by 5.50%, latest price at 0.115, total market value of 0.0213 billion, year-to-date increase of 155.56% [2] - 映恩生物-B: Increased by 5.00%, latest price at 336.000, total market value of 29.58 billion, year-to-date increase of 255.18% [2] - 基石药业-B: Increased by 4.66%, latest price at 7.190, total market value of 10.612 billion, year-to-date increase of 212.61% [2] - 三叶草生物-B: Increased by 4.39%, latest price at 2.140, total market value of 2.776 billion, year-to-date increase of 787.97% [2] - 百奥塞图-B: Increased by 3.86%, latest price at 24.220, total market value of 9.673 billion, year-to-date increase of 184.94% [2] - 来凯医药-B: Increased by 3.71%, latest price at 14.540, total market value of 6.49217 billion, year-to-date increase of 55.18% [2] - 君实生物: Increased by 3.29%, latest price at 27.600, total market value of 28.337 billion, year-to-date increase of 138.34% [2] - MIRXES-B: Increased by 3.26%, latest price at 72.900, total market value of 20.145 billion, year-to-date increase of 212.88% [2]

Core Viewpoint - The pharmaceutical stocks continue to rise, reflecting positive market sentiment and investor interest in the sector [1] Group 1: Stock Performance - Zai Lab Limited (荃信生物-B, 02509.HK) increased by 7.04%, reaching HKD 29.2 [1] - Junshi Biosciences (复宏汉霖, 02696.HK) rose by 6.84%, trading at HKD 75 [1] - I-Mab (映恩生物-B, 09606.HK) saw a gain of 5.41%, with shares priced at HKD 331 [1] - Rongchang Biologics (荣昌生物, 09995.HK) experienced a 5.53% increase, now at HKD 96.3 [1] - CanSino Biologics (康方生物, 09926.HK) grew by 5.25%, with a share price of HKD 128.4 [1]